Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age

Authors:

Abstract
Although antipsychotic drugs are of value in reducing the symptoms of schizophrenia,1,2 mortality, hospitalizations, and suicide3 as well as treating agitation, hallucinations, and delusions, they do not help negative symptoms or cognitive impairments4 and cause significant adverse effects.4 New directions in treatment of schizophrenia are urgently needed, but as in other fields of medicine,5 many promising new directions for treatment have been reported, but not later replicated.6 Well-replicated sex differences in the age of onset and course of schizophrenia indicate that estradiol might influence the course of schizophrenia.7 Several randomized clinical trials have been conducted on the administration of oral estradiol to female patients with schizophrenia; most, but not all, trials reported a beneficial effect.8 Three studies on estradiol patches in women with schizophrenia have been published. An initial 4-week pilot study in 36 women showed a decrease in positive symptoms using 100-μg estradiol patches9; this study was followed by a larger (N = 102) 4-week study showing improvements in positive symptoms and general psychopathology with the use of 100-μg estradiol patches in women with schizophrenia.10 A larger 8-week study of 183 women of childbearing age administered 100-μg and 200-μg estradiol patches vs placebo and showed significant improvements in positive symptoms (effect size, 0.44), general psychopathology subscale, and total Positive and Negative Syndrome Scale (PANSS) scores, with the higher dose showing greater effects.11 All studies used add-on designs in which estradiol or placebo was added to an antipsychotic drug; estradiol doses above 200 μg have not been tested.

This publication has 28 references indexed in Scilit: